Pricing
  1. JP-listed companies
  3. Financials
  4. Pretax margin (%)

【JP:4597】

Market cap
¥7B
P/E ratio
Develops and commercializes innovative cancer medicines across Asian markets including Japan, China, and South Korea, focusing on treatments and supportive care.
SummaryFinancialsDividendsHistoryOwnershipWorkforce
Period EndPretax margin (%) YoY (%)
Dec 31, 2025-209.1-66.31%
Dec 31, 2024-620.6+237.35%
Dec 31, 2023-184-19.39%
Dec 31, 2022-228.2-47.76%
Dec 31, 2021-436.9-52.31%
Dec 31, 2020-916.1+567.82%
Dec 31, 2019-137.2-82.16%
Dec 31, 2018-768.9+210.83%
Dec 31, 2017-247.4+150.70%
Dec 31, 2016-98.7-68.15%
Dec 31, 2015-309.7-94.73%
Dec 31, 2014-5,873.3-29.15%
Dec 31, 2013-8,290.3

Income Statement

RevenueRevenue growth (%)Cost of revenueGross profitGross margin (%)Research & developmentSelling, general & administrativeOperating margin (%)Operating expenses Operating income Income before tax Pretax margin (%)Provision for income taxesEffective tax rate (%)Net income Net income margin (%)Earnings per shareDiluted EPSDividend payout ratio (%)Dividend per shareEBITDAEBITDA margin (%)

Balance Sheet

Cash and cash equivalents Marketable securities, current Total cash & short-term investmentsAccounts receivable, netInventoriesTotal current assetsProperty, plant and equipment, netMarketable securities, non-current Total non-current assetsTotal assets Accounts payableShort-term debtLong-term debt, current Total current liabilitiesLong-term debt, non-current Total non-current liabilitiesTotal liabilities Common stock and paid-in capital Retained earningsStockholders' equityTotal debtNet debtD/E ratio (%)Working capital

Cash Flow

Depreciation & amortizationStock-based compensationCash from operations Capital expendituresCash from investing Payments for dividends Repurchases of common stockProceeds from issuance of term debt, netRepayments of term debtCash from financing Free cash flowFCF margin (%)